Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options

Cancer Biology & Medicine

Smitha P. Menon¹  Arpita Desai²  Grace K. Dy³ 

[1] ;Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226-0509, USA;

关键词: RAS;    RAF;    MEK;    receptor tyrosine kinases (RTK);    fibroblast growth factor receptor (FGFR);    non-small cell lung cance (NSCLC);   

DOI  :  10.20892/j.issn.2095-3941.2016.0008

来源: DOAJ

【 摘 要 】

During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in EGFR and translocations in ALK and ROS1 have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review, we highlight treatment options including corresponding clinical trials for oncogenic alterations affecting the receptor tyrosine kinases MET, FGFR, NTRK, RET, HER2, HER3, and HER4 as well as components of the RAS-RAF-MEK signaling pathway.

【 授权许可】

Unknown